Welcome to our dedicated page for Bridgebio Pharma SEC filings (Ticker: BBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BridgeBio Pharma, Inc. filings document a commercial-stage biopharmaceutical company focused on medicines for genetic conditions, including financial results, product revenue disclosures, program updates, and formal reports on ATTR-CM, LGMD2I/R9, and achondroplasia development programs.
Its SEC record includes Form 8-K disclosures for results of operations, Regulation FD presentations, clinical and regulatory press releases, material agreements, an at-the-market equity distribution agreement, convertible senior notes, and a board-authorized stock repurchase program. Proxy materials address director elections, executive compensation votes, auditor ratification, incentive plan share reserves, governance structure, and stockholder voting matters.
BridgeBio Pharma, Inc. (BBIO) Chief Executive Officer and director Kumar Haldea reported open-market sales of the company’s common stock on 11/20/2025 under a pre-arranged Rule 10b5-1 trading plan adopted on March 31, 2025. He sold 6,401 shares at a weighted average price of $64.9706, 14,299 shares at a weighted average price of $65.904, and 5,456 shares at a weighted average price of $66.7129, with each price reflecting sales across specified ranges. Following these transactions, Haldea directly held 228,776 shares and also had indirect beneficial ownership of 795,686 shares through the Kumar Haldea Family Irrevocable Trust and 4,598,447 shares through the Kumar Haldea Revocable Trust, where he serves as co-trustee and disclaims beneficial ownership except to the extent of any pecuniary interest.
BridgeBio Pharma, Inc. (BBIO) director insider transactions were reported on a Form 4. A reporting person serving as a director disclosed open-market sales of BridgeBio common stock on 11/17/2025 and 11/18/2025 at weighted average prices ranging from about $64.58 to $67.20 per share, with specific weighted averages of $66.6263, $67.056, $65.2315, and $66.049 for the reported trades.
Following these transactions, the director beneficially owned 17,887 shares of common stock directly and 50,583 shares indirectly through joint tenancy with Nancy N. Lo. The price ranges for each trade are available, and the reporting person has undertaken to provide detailed breakdowns of the individual sale prices within each range upon request.
BridgeBio Pharma, Inc. (BBIO) director reports option exercise and share sales. On 11/17/2025, the reporting person exercised a stock option for 10,000 shares of common stock at $16.75 per share, increasing their holdings before subsequent sales. That same day, they sold 3,801 shares of common stock at a weighted average price of $66.2481 and 6,199 shares at a weighted average price of $66.8908, all under a Rule 10b5-1 trading plan adopted on June 27, 2025. After these transactions, the reporting person directly owned 11,589 shares of BridgeBio common stock and indirectly owned 4,000 shares through Thinking Bench Capital LLC. Following the option exercise, 41,501 stock options with a $16.75 exercise price remained beneficially owned.
BridgeBio Pharma (BBIO) Chief Executive Officer and director Kumar Haldea reported routine equity activity on a Form 4 dated 11/16/2025. Several blocks of restricted stock units (RSUs) were converted into common stock as they vested, and a portion of the resulting shares was withheld to cover taxes.
Following these transactions, Haldea directly owns 254,932 shares of BridgeBio common stock. He also reports indirect beneficial ownership of 795,686 shares through the Kumar Haldea Family Irrevocable Trust and 4,598,447 shares through the Kumar Haldea Revocable Trust, where he is a co‑trustee and disclaims beneficial ownership beyond any pecuniary interest. The RSU awards vest quarterly over time as long as he continues serving the company, and the RSUs carry no expiration date.
BridgeBio Pharma, Inc. (BBIO) President and CFO reported stock transactions involving company common shares. On 11/16/2025, 21,317 shares were withheld to cover taxes upon vesting of 38,547 restricted stock units. On 11/17/2025, he sold 9,978 shares at a weighted average price of $66.1923 and 6,956 shares at a weighted average price of $66.8398, with sales executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 31, 2025. Following these transactions, he beneficially owns 382,830 BridgeBio common shares directly.
BridgeBio Pharma, Inc. (BBIO) reported an insider equity transaction by its Chief Accounting Officer on a Form 4. On 11/16/2025, the officer had 4,781 shares of common stock withheld, coded as transaction type "F," at a price of $66.39 per share. This withholding was used to cover tax obligations tied to the vesting of 9,410 shares of common stock underlying restricted stock units.
After this tax withholding, the reporting person beneficially owns 132,297 shares of BridgeBio Pharma common stock in direct ownership. The filing notes that the transaction relates to routine equity compensation vesting and associated tax settlement, rather than an open-market purchase or sale.
BridgeBio Pharma (BBIO) insider filed a Form 4 reporting open‑market sales totaling 80,000 shares of common stock on 11/06/2025 and 11/07/2025, executed under a Rule 10b5-1 trading plan adopted on March 31, 2025.
Sales were made through trusts where the reporting person is a co‑trustee at weighted average prices within disclosed ranges, with individual trades priced from $60.57 to $64.39 per share. Following these transactions, beneficial holdings reported include 4,598,447 shares (Revocable Trust), 795,686 shares (Family Irrevocable Trust), and 223,090 shares held directly.
BridgeBio Pharma (BBIO) disclosed an insider transaction by a director on 11/06/2025. The director exercised 61,031 stock options at $34.65 per share (code M), receiving shares that same day, and then sold 61,031 shares at a $63.7217 weighted average, within a $63.70–$63.88 range.
Following these trades, the director beneficially owned 16,991 common shares directly and 30,523 options remaining, which expire on 02/11/2030. The option grant vested in three annual installments from February 12, 2020 to February 12, 2023.
BridgeBio Pharma (BBIO): Director insider sales reported. On 10/29/2025, a director reported multiple open‑market sales by the Francis P. McCormick Rev Trust U/A DTD 1/27/2017 under a Rule 10b5‑1 plan adopted on August 28, 2024. Transactions included blocks of 111,755 and 43,393 shares, among others, at weighted average prices ranging from $65.4764 to $69.2358. Following the reported sales, 679,979 shares were beneficially owned indirectly by the trust.
BridgeBio Pharma (BBIO): Director transaction reported. A director executed a Rule 10b5-1 planned sale of 1,641 shares of common stock on 10/27/2025 at $65 per share. Following the sale, reported beneficial ownership stands at 878,338 shares held indirectly by the Francis P. McCormick Rev Trust U/A DTD 1/27/2017 and 83,275 shares held directly. The 10b5-1 plan was adopted on August 28, 2024.
BridgeBio Pharma (BBIO): Director transaction reported. A director executed a Rule 10b5-1 planned sale of 1,641 shares of common stock on 10/27/2025 at $65 per share. Following the sale, reported beneficial ownership stands at 878,338 shares held indirectly by the Francis P. McCormick Rev Trust U/A DTD 1/27/2017 and 83,275 shares held directly. The 10b5-1 plan was adopted on August 28, 2024.